Positron emission tomography of herpes simplex virus 1 oncolysis.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cancer Research

• Publication date

  2007-04-01

• Fields of study

  Biology, Medicine, Engineering

• Identifiers
  DOI 10.1158/0008-5472.CAN-06-4062PMID 17409438
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oncolytic herpes simplex virus mutants are more efficacious than wild‐type adenovirus Type 5 for the treatment of high‐risk neuroblastomas in preclinical models

  2005cited by this paper
• Selectivity of an Oncolytic Herpes Simplex Virus for Cells Expressing the DF3/MUC1 Antigen

  2004influential reference
• HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

  2004cited by this paper
• Molecular imaging of gene therapy for cancer

  2004cited by this paper
• Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression.

  2002cited by this paper
• Viral oncolysis.

  2002cited by this paper
• Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5.

  2002cited by this paper
• Regulation of herpes simplex virus γ134.5 expression and oncolysis of diffuse liver metastases by Myb34.5

  2002cited by this paper
• The potential for efficacy of the modified (ICP 34.5−) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

  2002cited by this paper
• Molecular imaging of cancer with positron emission tomography

  2002influential reference
• Regulation of Herpes Simplex Virus 1 Replication Using Tumor-Associated Promoters

  2002cited by this paper
• Oncolytic viruses

  2002cited by this paper
• PET imaging of gene expression.

  2002influential reference
• Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil.

  2001cited by this paper
• Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.

  2001cited by this paper
• Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer

  2001cited by this paper
• Reovirus as an oncolytic agent against experimental human malignant gliomas.

  2001cited by this paper
• Intralesional injection of herpes simplex virus 1716 in metastatic melanoma.

  2001cited by this paper
• Newcastle disease virus (NDV): brief history of its oncolytic strains.

  2000cited by this paper
• Quantitation of HSV mass distribution in a rodent brain tumor model

  2000cited by this paper
• Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

  2000cited by this paper
• Conditionally replicating herpes vectors for cancer therapy.

  2000cited by this paper
• Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

  2000cited by this paper
• Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

  2000cited by this paper
• Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

  2000cited by this paper
• An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma

  2000cited by this paper
• Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi‐mutated herpes simplex virus type‐1 (G207)

  1999cited by this paper
• Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase.

  1999cited by this paper
• Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors

  1998cited by this paper
• An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy

  1998cited by this paper
• Reovirus therapy of tumors with activated Ras pathway.

  1998cited by this paper
• Cancer gene therapy: connecting basic research with clinical inquiry.

  1998cited by this paper
• Therapeutic Efficiency and Safety of a Second-Generation Replication-Conditional HSV1 Vector for Brain Tumor Gene Therapy

  1997cited by this paper
• Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1.

  1995cited by this paper
• Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene.

  1994cited by this paper
• Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1

  1992cited by this paper
• Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant.

  1988cited by this paper

• Enhancing the Antitumor Efficacy of Oncolytic Adenovirus Through Sonodynamic Therapy-Augmented Virus Replication.

  2024cites this paper
• Oncolytic HSV1 targets different growth phases of breast cancer leptomeningeal metastases

  2023cites this paper
• Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice.

  2021cites this paper
• Noninvasive Imaging for Patients with COVID-19 and Acute Chest Pain

  2021cites this paper
• Deep learning of magnetic resonance fingerprints for the quantitative imaging of apoptosis following oncolytic virotherapy

  2021cites this paper
• Nuclear Medicine in Times of COVID-19: How Radiopharmaceuticals Could Help to Fight the Current and Future Pandemics

  2020cites this paper
• AI boosted molecular MRI for apoptosis detection in oncolytic virotherapy

  2020cites this paper
• E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications

  2020cites this paper
• Virotherapy: Current Trends and Future Prospects for Treatment of Colon and Rectal Malignancies

  2019cites this paper
• A model of breast cancer meningeal metastases: characterization with in vivo molecular imaging

  2018cites this paper
• Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery

  2017cites this paper
• Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress

  2016cites this paper
• Molecular Imaging of Smoke-Induced Changes in Nuclear Factor-Kappa B Expression in Murine Tissues Including the Lung

  2016cites this paper
• Cancer immunotherapy with a gene modified serotype 3 oncolytic virus

  2015cites this paper
• Molecular imaging of oncolytic viral therapy

  2015cites this paper
• Discovery and development of imaging-capable bacterial nitroreductases and their cytotoxic prodrugs for Clostridium sporogenes based gene therapy

  2015cites this paper
• CANCER IMMUNOTHERAPY WITH A GENE MODIFIED SEROTYPE 3 ONCOLYTIC ADENOVIRUS

  2015cites this paper
• Gene Therapy of Cancer

  2014cites this paper
• Rational development of radiopharmaceuticals for HIV-1.

  2014cites this paper
• Imaging of Oncolytic Virus Gene Expression

  2014cites this paper
• Molecular imaging with bioluminescence and PET reveals viral oncolysis kinetics and tumor viability.

  2014influential citation
• oncolysis kinetics and tumor viability Molecular imaging with bioluminescence and PET reveals viral

  2014cites this paper
• Characterization of a murine model of meningeal metastases from breast cancer

  2013cites this paper
• Viral Transduction of Human Cancer Cell Lines with an Optimized Triple Modality Reporter for Quantifiable Tumor Imaging and Therapy Evaluation In Vivo

  2013cites this paper
• Development of specific radiopharmaceuticals for infection imaging by targeting infectious micro-organisms.

  2012cites this paper
• Angiogenesis Inhibition Using an Oncolytic Herpes Simplex Virus Expressing Endostatin in a Murine Lung Cancer Model

  2012cites this paper
• Viral Oncolytic Therapeutics for Neoplastic Meningitis

  2012cites this paper
• A Vaccinia Virus Encoding the Human Sodium Iodide Symporter Facilitates Long-Term Image Monitoring of Virotherapy and Targeted Radiotherapy of Pancreatic Cancer

  2012cites this paper
• Positron Emission Tomography Reporter Genes and Reporter Probes: Gene and Cell Therapy Applications

  2012cites this paper
• Combination of pet imaging with viral vectors for identification of cancer metastases.

  2012cites this paper
• Theranostic Potential of Oncolytic Vaccinia Virus

  2012cites this paper
• Imaging Characteristics, Tissue Distribution, and Spread of a Novel Oncolytic Vaccinia Virus Carrying the Human Sodium Iodide Symporter

  2012cites this paper
• Oncolytic Herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation

  2011cites this paper
• Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus

  2011cites this paper
• Radiolabeled antiviral drugs and antibodies as virus-specific imaging probes

  2010influential citation
• Molecular Imaging with Reporter Genes: Molecular Imaging with Reporter Genes

  2010cites this paper
• Development of telomerase targeted gene therapy for treatment of cancer

  2008cites this paper
• PET and PET/CT for oncology applications in the abdomen and pelvis: Update and future directions in the age of molecular medicine

  2008cites this paper
• Utility of a herpes oncolytic virus for the detection of neural invasion by cancer.

  2008cites this paper
• Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice

  2007cites this paper
• Recent advances in the development of oncolytic HSV-1 vectors: 'arming' of HSV-1 vectors and application of bacterial artificial chromosome technology for their construction.

  2007cites this paper
• Dual-modality in vivo monitoring of subventricular zone stem cell migration and metabolism.

  2007cites this paper
• Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity.

  2007cites this paper
• Modeling of ( 18 F)-FHBG in Tumor and Normal Tissues

  2007cites this paper
• Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application.

  2007cites this paper